The FDA's Neurological Devices Panel will next month review CoAxia's NeuroFlo catheter for treatment of cerebral ischemia.
Privately held CoAxia Inc. landed a date with the FDA's Neurological Devices Panel to submit its NeuroFlo catheter for de novo approval.
The Minneapolis-based company's NeuroFlo device, which already has CE Marking for the European Union, aims to divert blood flow in the brain for patients suffering cerebral ischemia as a result of stroke, vasospasm, or other conditions.
The device boasts 35-50% improvement in cerebral perfusion and can be placed in 10-15 minutes via the abdominal aorta, according to the company's website.
Edwards Lifesciences reports 3rd-quarter sales and earnings growth in excess of 20% and raises its...
A federal jury in Texas reportedly clears Johnson & Johnson's DePuy Pinnacle hip implant in the...
Federal auditors say the FDA needs to ramp up its cybersecurity efforts in order to deter hackers.
ReFlow Medical announced FDA clearance for its Wingman35 crossing catheter.